Stock analysts at Cantor Fitzgerald began coverage on shares of Spero Therapeutics (NASDAQ:SPRO) in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $27.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 127.27% from the company’s previous close.

The analysts wrote, “Differentiated pipeline addresses large unmet needs in infectious disease. Spero has three development programs that target multibillion-dollar commercial opportunities. The company’s drugs focus on unmet needs inside and outside the hospital setting. Spero plans to commercialize its products using an accelerated path to market, saving investors time and money. The company’s three leading drugs: 1) SPR994/oral carbapenem, which could be the first new oral therapy for cUTI in 21 years. Unlike competing drugs, SPR994 will be covered outside the hospital formulary, where it will not compete with generics and be part of the bundle. The drug is being developed for UTI, but could also be used for IAI, blood stream infections, and CAP; 2) SPR741 and SPR206/IV potentiators address major unmet needs in the hospital setting and expand the utility of existing antibiotics; and, 3) the SPR720/NTM program is a novel oral bacterial gyrase inhibitor designed to treat a rare lung infection.””

A number of other research firms have also recently commented on SPRO. Oppenheimer started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set a “buy” rating and a $30.00 price objective for the company. Bank of America started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set a “neutral” rating for the company. ValuEngine upgraded Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Tuesday, January 30th. Finally, Cowen initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Spero Therapeutics has an average rating of “Hold” and a consensus price target of $24.25.

Shares of Spero Therapeutics (SPRO) opened at $11.88 on Thursday. Spero Therapeutics has a 1 year low of $9.84 and a 1 year high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.20 million. research analysts forecast that Spero Therapeutics will post -8.52 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in SPRO. Dean Capital Investments Management LLC bought a new stake in Spero Therapeutics during the fourth quarter valued at about $118,000. Atlas Venture Associates IX LLC bought a new stake in Spero Therapeutics during the fourth quarter valued at about $16,179,000. California Public Employees Retirement System bought a new stake in Spero Therapeutics during the fourth quarter valued at about $294,000. BlackRock Inc. bought a new stake in Spero Therapeutics during the fourth quarter valued at about $2,830,000. Finally, Artal Group S.A. bought a new stake in Spero Therapeutics during the fourth quarter valued at about $4,113,000. 0.01% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Spero Therapeutics (SPRO) Receives New Coverage from Analysts at Cantor Fitzgerald” was published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2018/02/10/spero-therapeutics-spro-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.

About Spero Therapeutics

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.